U.S. Court in Massachusetts Won’t Dismiss Whistleblower Action Against Janssen over Free Physician Advisory Services
- March 01, 2024
The disclosure of defendant Janssen Biotech, Inc.’s (Janssen’s) marketing practices in prior litigation wasn’t enough to put the government on notice of the fraud alleged in a whistleblower action that the pharmaceutical company provided kickbacks to physicians who prescribe its infusible drugs, Remicade and Simponi ARIA, a federal court in Massachusetts held February 16.
ARTICLE TAGS
You must be logged in to access this content.